COVID-19 Vaccine Combos Aim to Boost Immunity
COVID-19 Vaccine Combos Aim to Boost Immunity
Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.
COVID-19 Vaccine Combos Aim to Boost Immunity
COVID-19 Vaccine Combos Aim to Boost Immunity

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.

immunity
COVID-19 Hospitalizations Tank a Month After Vaccines Roll Out
COVID-19 Hospitalizations Tank a Month After Vaccines Roll Out
Asher Jones | Feb 23, 2021
Two preliminary reports from the UK provide real-world evidence in support of the Pfizer/BioNTech and Oxford-AstraZeneca vaccines.
Moderna Developing Booster Shot for New Virus Variant B.1.351
Moderna Developing Booster Shot for New Virus Variant B.1.351
Asher Jones | Jan 25, 2021
New data suggest that the company’s approved COVID-19 vaccine protects against different virus variants, but could be less effective against the one that originated in South Africa.
Introducing Inoculation, 1721
Introducing Inoculation, 1721
Max Kozlov | Jan 1, 2021
As a deadly smallpox outbreak ravaged Boston, one of the city’s leaders advocated for a preventive measure he’d learned about from Onesimus, an enslaved man.
Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy
Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy
Emma Yasinski | Sep 25, 2020
Adeno-associated viral vectors can deliver gene therapies, but AAV-neutralizing antibodies might prevent the medicines from working.
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Vector-Based Vaccines Come to the Fore in the COVID-19 Pandemic
Anthony King | Sep 8, 2020
Adenovirus vectors deliver the genetic instructions for SARS-CoV-2 antigens directly into patients’ cells, provoking a robust immune response. But will pre-existing immunity from common colds take them down?
COVID-19 Antibodies Last for at Least Four Months After Recovery
COVID-19 Antibodies Last for at Least Four Months After Recovery
Amanda Heidt | Sep 2, 2020
The results from a study in Iceland can’t say if a recovered patient’s antibodies can protect them from subsequent reinfection.
Patients Reinfected with Coronavirus in Hong Kong, Europe
Patients Reinfected with Coronavirus in Hong Kong, Europe
Lisa Winter | Aug 25, 2020
So far, there are three patients known to have been infected with SARS-CoV-2 twice, and in at least one case the second time around was asymptomatic.
Some COVID-19 Patients Lack Key Structures for Antibody Creation
Some COVID-19 Patients Lack Key Structures for Antibody Creation
Katarina Zimmer | Aug 25, 2020
An absence of germinal centers—which arise during infections to produce long-lived antibody-generating cells—might explain rapidly waning antibody levels in the disease.
Differences in Antibody Responses Linked to COVID-19 Outcomes
Differences in Antibody Responses Linked to COVID-19 Outcomes
Katarina Zimmer | Aug 18, 2020
In a small study of patients hospitalized due to SARS-CoV-2 infection, researchers report distinct early differences between the antibody responses of patients who recovered and those who died, possibly paving the way for a tool to predict disease prognosis.